Janux Therapeutics, Inc. · NASDAQ:JANX
Janux Therapeutics — Corporate Update (December 2024)
25 slides from Janux Therapeutics's corporate update, Dec 2, 2024
Slide 1: Program Updates December 2, 2024
Creating Transformative Medicines to Improve Patients’ Lives Program Updates December 2, 2024 Exhibit 99.2
Slide 2: Forward-Looking Statements and Disclaimers
Forward-Looking Statements and Disclaimers This presentation includes certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking sta
Slide 3: Multiple near-term high value opportunities in CD3 TCE targets
Janux – multiple near-term high value opportunities in CD3 TCE targets JANX007 Pipeline and Platform Cash Position *As of Sept 30, 2024, includes cash and cash equivalents JANX008 PSMAxCD3-TRACTr to treat mCRPC demonstrated substantial clinical activity Today’s update focuses upon efficacy and safet
Slide 4: TRACTr platform design principles
Janux Tumor Activated T-Cell Engager (TRACTr) platform design principles Each program is designed as a potent T-cell engager with reduced toxicity Emerging JANX007 clinical data demonstrates TRACTr platform can potentially improve both safety and efficacy compared to contemporary TCEs TRACTr Design
Slide 5: JANX007 clinical PK data consistent with TRACTr design principles
JANX007 clinical PK data continues to be consistent with TRACTr design principles Prolonged TRACTr exposure with minimal accumulation of activated TCE Systemic levels of activated TCE remain more than 100-fold lower than TRACTr across doses - Consistent with NHP safety studies and TRACTr design - 0.
Slide 6: JANX007 Update: Resetting the bar in prostate cancer
JANX007 Update Resetting the bar in prostate cancer
Slide 7: JANX007 clinical development focusing on pre-Pluvicto 2L and 3L settings
1L treatment: Enzalutamide Docetaxel Abiraterone 2L 3L+ Pluvicto + SOC Janux P1b will have readthrough into a potential multibillion dollar opportunity in 2L mCRPC JANX007 clinical development focusing upon pre-Pluvicto 2L and 3L settings PARPi combo 1L (80k) JANX007 Future Patient Opportunity Abi –
Slide 8: JANX007 dose escalation schema and update focus
0.1 mg C1 0.3 mg C2 0.05/0.1/0.3 mg C3 0.1/0.3/0.45 mg C4 0.1/0.3/1 mg C5 0.2/0.6/2 mg C6 0.3/1/3 mg C7 0.4/2/6 mg C8 0.3/1.5/6 mg C9 0.3/2/9 mg C10 JANX007 dose escalation schema and update focus QW cohorts prioritized to establish safety and efficacy profiles QW Dose Evaluations Current update coh
Slide 9: JANX007 patient characteristics
JANX007 patient characteristics Heavily pre-treated patients with a median of 4 prior lines of therapy *Number or prior lines of therapy does not include androgen deprivation therapy Characteristic Patients with target dose ≥2 mg QW n=16 Median age, years (range) 71.5 (54 – 79) Race, white / black /
Slide 10: JANX007 highly competitive clinical data profile supports early lines
JANX007 highly competitive clinical data profile supports development in early lines of therapy Resistance Driver Activity Encouraging Anti-Tumor Activity Patients with ≥90% PSA reduction PSA90: 17% 63% PSA99: 0% 31% PSA declines thru 12wks ≥PSA50 at 12-weeks: NE 75% ≥PSA90 at 12-weeks: NE 5
Slide 11: Deep PSA declines with predictable, transient CRS in 5L patients
Deep PSA declines coupled with predictable, transient and easily managed CRS in 5L pts Response rate not impacted by prior therapies Deep PSA declines in heavily treated 5L patient population regardless of prior taxane and ARPI use QW Dose Cohorts 0.2/0.6/2 mg 0.3/1/3 mg 0.4/2/6 mg 0.3/1.5/6 mg 0.3/
Slide 12: Deep PSA responses irrespective of resistance driver aberration status
Deep PSA responses irrespective of resistance driver aberration status JANX007 retained full activity against wild-type and resistant patient populations JANX007 demonstrated robust activity against wildtype and major drug resistance driver mutations/aberrations QW Dose Cohorts 0.2/0.6/2 mg 0.3/1/3
Slide 13: Anti-tumor responses in RECIST evaluable 5L patients
Encouraging anti-tumor responses in RECIST evaluable 5L patients supports progression to Ph1b studies Early indication of significant anti-tumor activity 5/8 patients had tumor reductions from baseline 4/8 patients had ≥30% tumor reductions from baseline 50% ORR†, 63% DCR† Competitor results** 30% O
Slide 14: Encouraging early signs of durability with JANX007
Encouraging early signs of durability with JANX007 Encouraging depth and durability of PSA declines supports development in earlier lines of therapy Deep and durable PSA declines in both measurable and bone only disease ≥ PSA50 at 12wks = 75% ≥ PSA90 at 12wks = 50% Encouraging early RECIST anti-tumo
Slide 15: Treatment guidance optimization and target dose escalation
Treatment guidance optimization and target dose escalation JANX007 exhibited predictable CRS onset and duration that rapidly responded to treatment < 24h Treatment with steroids beyond the resolution of CRS may negatively impact efficacy (red curves) New guidance provides opportunity to further impr
Slide 16: Potential impact of treatment guidance optimization
Potential impact of treatment guidance optimization Improved treatment guidance provides an opportunity to further improve JANX007 responses QW Dose Cohorts 0.2/0.6/2 mg 0.3/1/3 mg 0.4/2/6 mg 0.3/1.5/6 mg 0.3/2/9 mg *Non-optimal guidance
Slide 17: JANX007 well tolerated with a predictable safety profile
JANX007 was well tolerated with a predictable safety profile CRS and TRAEs have been transient and predominantly occurred in cycle 1 Majority of TRAEs occur in Cycle 1 Highest event incidence after step 1 dose CRS events in C2+ are infrequent and primarily associated with intra-patient escalation an
Slide 18: Predictable safety profile at weekly target dose ≥2 mg
Predictable safety profile in patients treated with weekly target dose ≥2 mg Majority of TRAEs were transient, predictable and known to be associated with CRS *Transient and asymptomatic AST/ALT elevations **G3 anemia reported in 2 patients with G1/2 at baseline Preferred Term TRAEs (max grade) in ≥
Slide 19: Pluvicto VISION study correlated PSA declines with rPFS and OS
Pluvicto VISION study correlated PSA declines up to 12 weeks with rPFS and OS JANX007 high rate of PSA50 and PSA90 declines at 12 weeks supports opportunity to achieve meaningful PFS/OS A high percentage of JANX007 treated-patients maintained PSA declines ≥PSA50 and PSA90 at 12 weeks and supports an
Slide 20: JANX007 5L study compared with other therapies
Characteristic Median Tx line mPFS ORR Best PSA decline ≥ 50% Best PSA decline ≥ 90% ≥ PSA50 at 12wks** ≥ PSA90 at 12wks** JANX007 (≥ 2mg target) 5L 7.4 mo† (8/16 IP*) Pluvicto + SOC (7.4 GBq) 3L 8.7 mo (SOC 3.4 mo) AMG509 (≥ 0.75 mg target) 4L 7.8 mo NR ARX517 (≥ 2 mg) 5L NR NR NR JANX007 5L study
Slide 21: Current 2L mCRPC treatments highlight the opportunity for JANX007
Current 2L mCRPC treatments highlight the opportunity for JANX007 JANX007 5L results compare favorably to 2L drugs 1L Treatment 2L PFS (months) ORR PSA90 PSA50 Abi 2.9 Doc 6.8 Enza 8.1 Doc 4.4 Abi 5.6 Enza 8.3 Pluvicto 11.6 Enzalutamide Abiraterone Docataxel 0% 39% 12% 11% 14% 29% ARPi or Abi 13% 43
Slide 22: JANX007 positioned across the continuum of prostate cancer care
JANX007 is positioned to treat patients across the continuum of prostate cancer care Interventional therapy (nmCSPC, mCSPC) ~260K 1L mCRPC 3L+ mCRPC Hormonal therapy (nmCSPC, mCSPC) ~150K PFS:~33+mo OS: ~50mo JANX007 has the potential to address a broad segment of prostate cancer patients 2L mCRPC H
Slide 23: JANX007 – resetting the bar in prostate cancer
JANX007 – resetting the bar in prostate cancer Encouraging early data highlights potential for best-in-treatment opportunity Resistance Driver Activity Encouraging Anti-Tumor Activity PSA50: PSA90: AR mutants, variant-7, amplifications; BRCA1/2, PI3K, PTEN, TP53 PSA50 100%, PSA90 54% ORR†: DCR†: Dee
Slide 24: JANX007 – clinical plans and opportunities
JANX007 – clinical plans and opportunities Large Opportunity Proof-of-Principle Forward Momentum JANX007’s unique MoA generated safety window potentially enables substantial efficacy in heavily treated patients Clinical development plan will focus upon pre-Pluvicto 2L and 3L patients Two QW step dos
Slide 25: David Campbell, Ph.D. President and CEO
David Campbell, Ph.D. President and CEO 10955 Vista Sorrento Parkway San Diego, CA 92130 dcampbell@januxrx.com
Janux Therapeutics — Corporate Update (December 2024) on 6ix